Advertisement

The discovery and development of Viagra® (sildenafil citrate)

Chapter
Part of the Milestones in Drug Therapy MDT book series (MDT)

Abstract

Sildenafil citrate (UK-92,480, Viagra®) is a selective inhibitor of phosphodiesterase type 5 (PDE5) and acts on the nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) pathway [1, 2]. UK-92,480 was first synthesised in the Sandwich laboratories of Pfizer Ltd, UK in 1989, and resulted from a discovery programme aimed at developing a selective inhibitor of PDE5. The origins of the project that eventually led to the discovery and development of Viagra date from around the mid 1980s. At this time, scientists working at the Pfizer European Research Centre were interested in potential new approaches to the treatment of several cardiovascular diseases.

Keywords

Nitric Oxide Erectile Dysfunction Multiple System Atrophy Erectile Function Corpus Cavernosum 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jeremy JY, Ballard SA, Naylor AM, Miller MAW, Angelini GD (1997) Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. Br J Urol 79: 958–963PubMedCrossRefGoogle Scholar
  2. 2.
    Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, Osterloh IH, Gingell C (1996) Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 8: 47–52PubMedGoogle Scholar
  3. 3.
    Moncada S, Higgs A (1993) The L-arginine-nitric oxide pathway. N Engl J Med 329: 2002–2012PubMedCrossRefGoogle Scholar
  4. 4.
    Hare TM, Colucci WS (1995) Role of nitric oxide in the regulation of myocardial function. Prog Cardiovasc Dis 38: 155–166CrossRefGoogle Scholar
  5. 5.
    Beavo JA (1995) Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 75: 725–748PubMedGoogle Scholar
  6. 6.
    Terrett N, Bell A, Brown D, Ellis P (1996) Sildenafil (Viagra), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction. Bioorg Med Chem Lett 6: 1819–1824CrossRefGoogle Scholar
  7. 7.
    Ballard SA, Gingell CJ, Tang K, Turner LA, Price ME, Naylor AM (1998) Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 159: 2164–2171PubMedCrossRefGoogle Scholar
  8. 8.
    Lue TF (2000) Erectile dysfunction. N Engl J Med 342: 1802–1813PubMedCrossRefGoogle Scholar
  9. 9.
    Jackson G, Benjamin N, Jackson N, Allen MJ (1999) Effects of sildenafil citrate on human hemodynamics. Am J Cardiol 83: 13C–20CPubMedCrossRefGoogle Scholar
  10. 10.
    Wallis RM, Corbin JD, Francis SH, Ellis P (1999) Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 83: 3C–12CPubMedCrossRefGoogle Scholar
  11. 11.
    Muirhead GJ, Rance DJ, Walker DK, Wastall P (2002) Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil. Br J Clin Pharmacol 53 (Suppl 1): 13S–20SPubMedCrossRefGoogle Scholar
  12. 12.
    Nichols DJ, Muirhead GJ, Harness JA (2002) Pharmacokinetics of sildenafil citrate after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol 53: 5S–12SPubMedCrossRefGoogle Scholar
  13. 13.
    Webb DJ, Freestone S, Allen MJ, Muirhead GJ (1999) Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol 83: 21C–28CPubMedCrossRefGoogle Scholar
  14. 14.
    Boolell M, Gepi-Attee S, Gingell JC, Allen MJ (1996) Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 78: 257–261PubMedCrossRefGoogle Scholar
  15. 15.
    Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A (1997) The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 49: 822–830PubMedCrossRefGoogle Scholar
  16. 16.
    Montorsi F, McDermott TE, Morgan R, Olsson A, Schultz A, Kirkeby HJ, Osterloh IH (1999) Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies. Urology 53: 1011–1018PubMedCrossRefGoogle Scholar
  17. 17.
    Dinsmore WW, Hodges M, Hargreaves C, Osterloh IH, Smith MD, Rosen RC (1999) Sildenafil citrate (VIAGRA) in erectile dysfunction: near normalization in men with broad-spectrum erectile dysfunction compared with age-matched healthy control subjects. Urology 53: 800–805PubMedCrossRefGoogle Scholar
  18. 18.
    Kloner RA, Brown M, Prisant LM, Collins M (2000) Efficacy and safety of Viagra (sildenafil citrate) in patients with erectile dysfunction taking concomitant antihypertensive therapy. Am J Hypertens 14: 70–73CrossRefGoogle Scholar
  19. 19.
    Conti CR, Pepine CJ, Sweeney M (1999) Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease. Am J Cardiol 83: 29C–34CPubMedCrossRefGoogle Scholar
  20. 20.
    Olsson AM, Persson CA (2001) Efficacy and safety of sildenafil citrate for the treatment of erectile dysfunction in men with cardiovascular disease. Int J Clin Pract 55: 171–176PubMedGoogle Scholar
  21. 21.
    Rendell MS, Rajfer J, Wicker PA, Smith MD, for the Sildenafil Diabetes Study Group (1999) Sildenafil for treatment of erectile dysfunction in men with diabetes. JAMA 281: 421–426PubMedCrossRefGoogle Scholar
  22. 22.
    Giuliano F, Hultling C, El Masry WS, Smith MD, Osterloh IH, Orr M, Maytom M (1999) Randomized trial of sildenafil for the treatment of erectile dysfunction in spinal cord injury. Ann Neurol 46: 15–21PubMedCrossRefGoogle Scholar
  23. 23.
    Derry FA, Dinsmore WW, Fraser M, Gardner BP, Glass CA, Maytom MC, Smith MD (1998) Efficacy and safety of oral sildenafil (VIAGRA) in men with erectile dysfunction caused by spinal cord injury. Neurology 51: 1629–1633PubMedCrossRefGoogle Scholar
  24. 24.
    Zippe CD, Kedia AW, Kedia K, Nelson DR, Agarwal A (1998) Treatment of erectile dysfunction after radical prostatectomy with sildenafil citrate (Viagra). Urology 52: 963–966PubMedCrossRefGoogle Scholar
  25. 25.
    Lowentritt BH, Scardino PT, Miles BJ, Orejuela FJ, Schatte EC, Slawin KM, Elliott SP, Kim ED (1999) Sildenafil citrate after radical retropubic prostatectomy. J Urol 162: 1614–1617PubMedCrossRefGoogle Scholar
  26. 26.
    Wagner G, Montorsi F, Auerbach S, Collins M (2001) Sildenafil citrate (VIAGRA) improves erectile function in elderly patients with erectile dysfunction: a subgroup analysis. J Gerontol A Biol Sci Med Sci 56: M113—M119PubMedCrossRefGoogle Scholar
  27. 27.
    Hussain IF, Brady CM, Swinn MJ, Mathias CJ, Fowler CJ (2001) Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson’s disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 71: 371–374PubMedCrossRefGoogle Scholar
  28. 28.
    Fowler C, Miller J, Sharief M (1999) Viagra (sildenafil citrate) for the treatment of erectile dysfunction in men with multiple sclerosis. Ann Neurol 46: 497Google Scholar
  29. 29.
    Chen J, Mabjeesh NJ, Greenstein A, Nadu A, Matzkin H (2001) Clinical efficacy of sildenafil in patients on chronic dialysis. J Urol 165: 819–821PubMedCrossRefGoogle Scholar
  30. 30.
    Rosas SE, Wasserstein A, Kobrin S, Feldman HI (2001) Preliminary observations of sildenafil treatment for erectile dysfunction in dialysis patients. Am J Kidney Dis 37: 134–137PubMedCrossRefGoogle Scholar
  31. 31.
    Prieto Castro RM, Anglada Curado FJ, Regueiro Lopez JC, Leva Vallejo ME, Molina Sanchez J, Saceda Lopez JL, Requena Tapia MJ (2001) Treatment with sildenafil citrate in renal transplant patients with erectile dysfunction. BJU Int 88: 241–243PubMedCrossRefGoogle Scholar
  32. 32.
    Chait J, Kobashigawa J, Chuang J, Moriguchi J, Kawata N, Laks H (1999) Efficacy and safety of sildenafil citrate (Viagra) in male heart transplant patients. J Heart Lung Transplant 18: 58Google Scholar
  33. 33.
    Wagoner LE, Giesting RM, Bell BJ, McGuire NC, Abraham WT (1999) Is Viagra (sildenafil) safe and effective in cardiac transplant recipients? Transplantation 67: S102CrossRefGoogle Scholar
  34. 34.
    Webster L, Michelakis E, Davis T, Tsuyuki R, Archer S (2002) Sildenafil is safe and effective treatment for erectile dysfunction in males with NYHA class II-III congestive heart failure. Circulation 106 (Suppl. 2): 11–469Google Scholar
  35. 35.
    Seidman SN, Roose SP, Menza MA, Shabsigh R, Rosen RC (2001) Treatment of erectile dysfunction in men with depressive symptoms: results of a placebo-controlled trial with sildenafil citrate. Am J Psychiatry 158: 1623–1630PubMedCrossRefGoogle Scholar
  36. 36.
    Morales A, Gingell C, Collins M, Wicker PA, Osterloh IH (1998) Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction. Int J Impot Res 10: 69–74PubMedCrossRefGoogle Scholar
  37. 37.
    Laties AM, Zrenner E (2002) Viagra® (sildenafil citrate) and ophthalmology. Prog Retin Eye Res 21: 485–506PubMedCrossRefGoogle Scholar
  38. 38.
    Corbin JD, Francis SH (2002) Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract 56: 453–459PubMedGoogle Scholar
  39. 39.
    Padma-Nathan H, Eardley I, Kloner RA, Laties AM, Montorsi F (2002) A 4-year update on the safety of sildenafil citrate (Viagra®). Urology 60 (Suppl. 2B): 67–90PubMedCrossRefGoogle Scholar
  40. 40.
    Sadovsky R, Miller T, Moskowitz M, Hackett G (2001) Three-year update of sildenafil citrate (Viagra) efficacy and safety. Int J Clin Pract 55: 115–128PubMedGoogle Scholar
  41. 41.
    Shakir SAW, Wilton LV, Boshier A, Layton D, Heeley E (2001) Cardiovascular events in users of sildenafil: results from first phase of prescription event monitoring in England. BMJ 322: 651–652PubMedCrossRefGoogle Scholar
  42. 42.
    Zusman R, Collins M (1999) Effect of sildenafil on blood pressure in men with erectile dysfunction taking concomitant antihypertensive medications. J Am Coll Cardiol 33: 238AGoogle Scholar
  43. 43.
    Zusman RM, Morales A, Glasser DB, Osterloh IH (1999) Overall cardiovascular profile of sildenafil citrate. Am J Cardiol 83: 35C–44CPubMedCrossRefGoogle Scholar
  44. 44.
    Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA (1998) Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 338: 1397–1404PubMedCrossRefGoogle Scholar
  45. 45.
    Fagelman E, Fagelman A, Shabsigh R (2001) Efficacy, safety, and use of sildenafil in urologic practice. Urology 57: 1141–1144PubMedCrossRefGoogle Scholar
  46. 46.
    Marks LS, Duda C, Dorey FJ, Macairan ML, Santos PB (1999) Treatment of erectile dysfunction with sildenafil. Urology 53: 19–24PubMedCrossRefGoogle Scholar
  47. 47.
    Jarow JP, Burnett AL, Geringer AM (1999) Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment. J Urol 162: 722–725PubMedCrossRefGoogle Scholar
  48. 48.
    Moreira SG, Brannigan RE, Spitz A, Orejuela FJ, Lipshultz LI, Kim ED (2000) Side-effect profile of sildenafil citrate (Viagra) in clinical practice. Urology 56: 474–476PubMedCrossRefGoogle Scholar
  49. 49.
    Moore R, Edwards J, McQuay H (2002) Sildenafil (Viagra) for male erectile dysfunction: a meta-analysis of clinical trial reports. BMC Urol 2: 1–12CrossRefGoogle Scholar
  50. 50.
    Fink HA, Mac Donald R, Rutks IR, Nelson DB, Wilt TJ (2002) Sildenafil for male erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med 162: 1349–1360PubMedCrossRefGoogle Scholar
  51. 51.
    Carson CC, Burnett AL, Levine LA, Nehra A (2002) The efficacy of sildenafil citrate (Viagra®) in clinical populations: an update. Urology 60 (Suppl 2B): 12–27PubMedCrossRefGoogle Scholar
  52. 52.
    Berman JR, Berman LA, Toler SM, Gill J, Haughie S for the Sildenafil Study Group (2003) Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: a double-blind, placebo-controlled study. J Urol 170: 2333–2338PubMedCrossRefGoogle Scholar
  53. 53.
    Caruso S, Intelisano G, Lupo L, Agnello C (2001) Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, cross-over, placebo-controlled study. Br J Obs Gynaecol 108: 623–628Google Scholar
  54. 54.
    Nurnberg H, Hensley P, Lauriello J, Parker L, Keith S (1999) Sildenafil for women patients with antidepressant-induced sexual dysfunction. Psychiatr Sery 50: 1076–1078Google Scholar
  55. 55.
    Mark A, Shifren J (2003) Medical therapy for female sexual dysfunction. Prim Care Update Ob/Gyns 10: 40–43CrossRefGoogle Scholar
  56. 56.
    Reffelmann T, Kloner RA (2003) Therapeutic potential of phosphodiesterase 5 inhibition fn for cardiovascular disease. Circulation 108: 239–244PubMedCrossRefGoogle Scholar
  57. 57.
    Zhang R, Wang Y, Zhang L, Zhang Z, Tsang W, Lu M, Zhang L, Chopp M (2002) Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats. Stroke 33: 2675–2680PubMedCrossRefGoogle Scholar
  58. 58.
    Vlachopoulos C, O’Rourke MF, Hirata K (2001) Sildenafil (Viagra®) improves the elastic properties of the aorta. Am J Hypertens 14: 6AGoogle Scholar
  59. 59.
    Mahmud A, Hennessy M, Feely J (2001) Effect of sildenafil on blood pressure and arterial wave reflection in treated hypertensive men. J Hum Hypertens 15: 707–713PubMedCrossRefGoogle Scholar
  60. 60.
    Lepore JJ, Maroo A, Pereira NL, Ginns LC, Dec GW, Zapol WM, Bloch KD, Semigran MJ (2002) Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am J Cardiol 90: 677–680PubMedCrossRefGoogle Scholar
  61. 61.
    Watanabe H, Ohashi K, Takeuchi K, Yamashita K, Yokoyama T, Tran QK, Satoh H, Terada H, Ohashi H, Hayashi H (2002) Sildenafil for primary and secondary pulmonary hypertension. Clin Pharmacol Ther 71: 398–402PubMedCrossRefGoogle Scholar
  62. 62.
    Abrams D, Schulze-Neick I, Magee A (2000) Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 82: E4CrossRefGoogle Scholar
  63. 63.
    Carroll WD, Dhillon R (2003) Sildenafil as a treatment for pulmonary hypertension. Arch Dis Child 88: 827–828PubMedCrossRefGoogle Scholar
  64. 64.
    Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Kreckel A, Weissmann N, Ghofrani S, Enke B, Seeger W, Grimminger F (2003) Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 42: 158–164PubMedCrossRefGoogle Scholar
  65. 65.
    Hirata K, Adji A, Vlachopoulos C, O’Rourke MF (2003) Sildenafil improves left ventricular systolic function in patients with congestive heart failure: the role of wave reflections. J Am Coll Cardiol 41 (Suppl A): 264ACrossRefGoogle Scholar
  66. 66.
    Katz SD (2003) Potential role of type 5 phosphodiesterase inhibition in the treatment of congestive heart failure. Congest Heart Fail 9: 9–15PubMedCrossRefGoogle Scholar
  67. 67.
    Lichtenstein JR (2003) Use of sildenafil citrate in Raynaud’s phenomenon: comment on the article by Thompson et al. Arthritis Rheum 48: 282–283PubMedCrossRefGoogle Scholar
  68. 68.
    Francis SH, Turko IV, Corbin JD (2001) Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Bio 65: 1–52CrossRefGoogle Scholar

Copyright information

© Springer Basel AG 2004

Authors and Affiliations

  1. 1.Viagra Medical StrategiesPfizer LtdSandwich, KentUK

Personalised recommendations